The oncogenic JAK2V617F mutation is found in myeloproliferative neoplasms (MPN) and is believed to be critical for leukemogenesis. Here we show that JAK2V617F requires an intact SH2 domain for constitutive activation of downstream signaling pathways.
Introduction
The V617F mutation within the pseudokinase domain of the non-receptor tyrosine kinase JAK2 (janus kinase 2) has frequently been identified in patients with myeloproliferative neoplasms (MPN) such as polycythaemia vera (PV; 95%), idiopathic myelofibrosis (IMF; 50%) and essential thrombocythaemia (ET; 20-40%) [1] [2] [3] [4] . In addition to MPN, JAK2V617F has also been observed at lower frequencies in chronic myelomonocytic leukemia (3-8%), myelodysplastic syndrome (4%), and rarely in systemic mastocytosis 5, 6 . A subset of JAK2V617F-negative PV patients showed gain of function mutations affecting exon 12 of JAK2 7 . The high abundance of JAK2 mutations led to the revision of the WHO diagnostic criteria for PV, ET and IMF 8 . In mice, transplantation of JAK2V617F-infected bone marrow to irradiated recipients led to a PV-like disease [9] [10] [11] [12] . Recently, Xing et al.
demonstrated that JAK2V617F-transgenic mice develop a MPN with ET-, PV-and (post-PV)
IMF-like phenotypes 13 . Tiedt et al. showed that the ratio of mutant JAK2V617F to wildtype JAK2 determines the MPN phenotype (ET vs. PV) in transgenic mice 14 .
Numerous cytokine type I receptors do not have an intrinsic tyrosine kinase domain and require JAK2 for signal transduction 15 . In Epo receptor (EpoR)-expressing cells, it has been proposed that ligand binding leads to a conformational change of the receptor, which promotes JAK2 activation through reciprocal interaction and phosphorylation of two juxtapositioned JAK2 molecules 16 . Subsequently, activated JAK2 phosphorylates tyrosine residues within the cytoplasmic tail of the cytokine receptor, which then serve as docking sites for signal transducers and activators of transcription (STATs), in particular STAT5 [17] [18] [19] .
Since JAK2 is essential for EpoR signaling, JAK2-/-mice are embryonic lethal due to severe anemia 20, 21 .
It has been demonstrated that JAK2V617F-mediated transformation of Ba/F3 cells is facilitated by the expression of homodimeric type I cytokine receptor such as the EpoR . However, parental Ba/F3 cells expressing JAK2V617F but lacking the EpoR are also able to proliferate IL-3-independently 2, 24 . These results indicate that the interaction between cytokine receptors and JAK2V617F may be crucial for oncogenic transformation, even though the exact mechanism and receptor requirements remain largely unclear.
The four mammalian JAK family members (JAK1, JAK2, JAK3 and Tyk2) contain seven conserved domains, which are designated as JAK homology (JH) domains JH1-JH7.
JH1 is a functional tyrosine kinase domain that becomes activated following cytokine
For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From stimulation. Phosphorylation of Y1007 in the activation loop of the kinase domain is required for JAK2 kinase activity 25 . The pseudokinase domain (JH2) is adjacent to the kinase domain (JH1) and is thought to play a role in auto-inhibition of the kinase activity of JAK2.
Homology based molecular modeling of JH2 showed three inhibitory regions (IR1-3), which mediate intermolecular interaction with the JH1 domain and regulate JAK2 kinase activity 26 .
The proximity of the recently discovered V617F mutation to the IR1 of the JH2 domain may explain the constitutive activity of JAK2V617F. However, there is no conclusive explanation for the inhibitory function of the JH1 domain, since the complete three-dimensional structure of any JAK member has not been reported yet. The N-terminal FERM domain mediates binding of JAK2 to membrane proximal regions of cytokine receptors as well as processing and surface expression of EpoR [27] [28] [29] [30] . Consistent with these reports, mutation of the FERM domain impairs the JAK2V617F-induced transformation in both Ba/F3 cell lines and in mice 31 . The presence of a SH2-like domain located between the FERM and the pseudokinase domain has been identified using structure prediction tools, but the function of the JAK2 SH2 domain has not been determined yet [32] [33] [34] . A mutation of the highly conserved arginine at position 426 within the SH2 domain of JAK2 did not have an impact on interferon-γ signaling 35 . Radtke et al. were able to show that the SH2 domain of JAK1 does not exert the function of a classical SH2 domain, but might mediate receptor binding and receptor surface expression 36 .
Since the SH2 domain is adjacent to the pseudokinase domain containing the V617F mutation, we hypothesized a possible role of the SH2 domain for the constitutive phosphorylation of JAK2V617F. Our goal was to determine the role of the SH2 domain in JAK2V617F-mediated transformation and myeloproliferation. Using both cell lines as well as a murine bone marrow transplantation model, we were able to find evidence for a SH2-dependent mechanism required for oncogenic activation of JAK2.
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Materials and methods

Cell lines
Murine Ba/F3 were obtained from the DSMZ (Braunschweig, Germany) and were grown in RPMI1640 medium containing 10% fetal calf serum in the presence of murine interleukin-3 (mIL-3) (R+D systems, Wiesbaden, Germany). 293T and γ2A cells were maintained in Dulbecco modified eagle medium (Gibco) containing 10% fetal calf serum.
Proliferation and viability
Proliferation was measured using an MTS (3-(4,5 dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H-tetrazolium)-based method by absorption of formazan at 490 nm (CellTiter 96; Promega, Madison, WI). Measures were taken as triplicates after 72h and 96h of culture without cytokines. Cell viability was determined by trypan blue exclusion method.
Immunoblotting
Immunoblotting was performed as previously described 37 . Antibodies to phospho- Membrane fractionation and EpoR surface staining was done as described previously 38 , 30 .
In vitro kinase assay
In vitro kinase assays were performed as described previously 39 . (Roche) was used as a substrate.
Expression vectors
Human wt jak2 cDNA was purchased from RZPD (Berlin, Germany). wt jak2 was cloned into the EcoR1 site of the MigRI retroviral vector co-expressing enhanced green fluorescent protein (eGFP). The Flag tag sequence was generated at the N-terminus of JAK2
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 6 by site directed mutagenesis (Quickchange, Stratagene, Heidelberg, Germany). The V617F, R426K and Y40A/L41A mutations were inserted by site-directed mutagenesis (Quickchange, Stratagene, Heidelberg, Germany) and confirmed by DNA sequencing. MSCV-eGFP-HAEpoR cDNA was kindly provided by Harvey Lodish. EpoR-Ba/F3 cell lines were generated by retroviral transduction followed by Epo-selection. Myc-tagged WT and mutant JAK2 were generated by cloning wt jak2 into the EcoR1 site of pCMV-Myc and subsequentely subcloned into the retroviral MSCV-neo vector. Ba/F3 cells were retrovirally transduced and GFPpositive Ba/F3 cells were sorted by flow cytometry.
Bone marrow transduction and transplantation
See supplementary methods for details. All experiments were approved by the expression with or without mutations in the SH2 domain or FERM domain was not able to render Ba/F3 cells growth factor-independent, which was determined by both MTS assay and cell counting ( Figure 1A ). In contrast, expression of JAK2V617F in Ba/F3 cells led to factorindependent growth as described previously 2 . JAK2V617F containing the FERM domain (JAK2 mFERM) mutation did not lead to this phenotype in Ba/F3 cells indicating that proper receptor scaffold is required for oncogenic JAK2-induced growth factor independence. Most strikingly, also cells expressing oncogenic JAK2V617F with the SH2 mutation (R426K) did not grow IL-3-independent ( Figure 1A ). These findings strongly indicate a critical role of both the FERM and the SH2 domain for the transforming function of oncogenic JAK2V617F.
JAK2V617F is constitutively phosphorylated in a ligand-independent manner resulting in cell growth in the absence of cytokines. We therefore determined the impact of the SH2 and FERM mutation on JAK2 and STAT5 phosphorylation ( Figure 1B Since JAK2V617F could further be activated by the addition of IL-3, we were interested to determine whether cytokine receptor expression is a prerequisite for the constitutive activation of this oncogene. We therefore stably reconstituted JAK2-deficient γ2A cells with WT and oncogenic JAK2 (supplemental Figure 1) . Even in the presence of IL-3 cells with WT-JAK2 expression did not show JAK2 or STAT5 activation. Strikingly, also oncogenic JAK2V617F did not display any activity in these cells. Thus, JAK2-deficient γ2A cells do not express functional common cytokine receptors required for constitutive JAK2 activation. Interestingly, these cells express the IL-3R alpha chain but lack IL-3R beta chain expression ( Figure 1C ). Ectopic expression of the IL-3R beta chain was sufficient to restore oncogenic JAK2 activity indicating a strict requirement of cytokine receptor expression for its oncogenic activation ( Figure 1C ).
Finally, we aimed to investigate the role of the SH2 domain in cytokine-induced activation of WT-JAK2. To this end the phosphorylation of WT-JAK2 and JAK2 mSH2 in γ2A cells, ectopically expressing the human IL-3R with and without IL-3 stimulation was determined. JAK2 mSH2 showed a detectable but considerably decreased autophosphorylation and STAT5 phosphorylation compared to WT-JAK2 after IL-3 stimulation ( Figure 1D ). Thus, the JAK2 SH2 domain may be required for both oncogenic and cytokine-induced JAK2 activation. we demonstrated that EpoR maturation was impaired in the absence of JAK2 and restored after WT-JAK2 reconstitution by using a FACS-based method (supplemental Figure 3B) .
Similarly, JAK2 mSH2 was able to induce maturation of the EpoR, again confirming that the SH2 domain is dispensable for receptor maturation. Interestingly, also oncogenic JAK2V617F
and JAK2V617F mSH2 induced EpoR maturation to the same extent than WT-JAK2
(supplemental Figure 3C ). Maturation of EpoR in γ 2A cells was also confirmed by treatment
with Endo H (supplemental Figure 3D ).
Thus, these findings suggest that in contrast to FERM domain-mutated JAK2, the lack of constitutive activation of the SH2-mutatetd JAK2V617F cannot be ascribed to impaired membrane and receptor association. Moreover, EpoR maturation and surface expression was not dependent on an intact SH2 domain. We also excluded the possibility that the mutation on the SH2 domain leads to reduced stability of JAK2V617F (supplemental Figure 5A ) or significantly compromised kinase activity (supplemental Figure 5B ).
Protein-protein interaction and transphosphorylation of JAK2V617F is dependent on an intact SH2 domain
The function of the SH2 domain in JAK proteins is largely unclear and the binding of the JAK SH2 domain to specific phosphorylated tyrosine residues could not be demonstrated so far 36 . Pull down experiments with GST-JAK2 SH2 revealed no tyrosine-phosphorylated binding partners. However, GST-JAK2 SH2 is able to precipitate JAK2 itself (data not shown).
Since the SH2 domain therefore might be crucial for JAK2 self-association and subsequent transphosphorylation, we investigated the interaction between JAK2 molecules by flag co-IP using both flag-tagged and myc-tagged JAK2 expression constructs. Both constructs showed comparable pJAK2 signal, STAT5 signaling and transforming ability in To determine the role of the SH2 domain for JAK2V617F self-association, we performed co-IP experiments using flag-and myc-tagged JAK2V617F mSH2 ( Figure 4B ).
Again, JAK2V617F revealed reciprocal interactions as well as high levels of constitutive phosphorylation. In contrast, overexpressed flag-tagged and myc-tagged JAK2V617F mSH2
could not be co-immunoprecipitated. This indicates that the SH2 domain seems to be crucial for the complex formation and subsequent transphosphorylation of JAK2V617F proteins. To further confirm these results, we performed additional co-immunoprecipitation experiments using flag-tagged JAK2V617F and myc-tagged WT-JAK2 and vice versa (Supplemental phosphorylation. Consistent with our previous data, phosphorylation of JAK2V617F was almost completely abrogated when the SH2 domain was mutated in both constructs.
Interestingly, flag-JAK2V617F mSH2 was partially phosphorylated when myc-JAK2V617F 45 . Therefore, JAK2 inhibition might be an attractive pharmacological approach for the treatment of MPN patients, which led to the initiation of several phase I and II studies 46 .
Although JAK2V617F is of major clinical interest, the mechanism leading to the constitutive activation of JAK2V617F is largely unclear.
In general, JAK2 is able to bind to numerous cytokine receptors, but the receptor type Unlike the kinase, pseudokinase, and FERM domain, the function of the JAK2 SH2
like domain in cytokine-induced and constitutive JAK2 activation is poorly understood. In this paper we provide evidence that the oncogenic and -to a lesser extent-cytokine-dependent JAK2 activation relies on a functional SH2 domain in the presence of the IL-3R. In For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Reciprocal JAK phosphorylation is thought to occur as the first phosphorylation step upon ligand binding and receptor dimerization 17, 48 . It has been demonstrated that the phosphorylation of several tyrosine residues including Y1007 within the activation loop are essential for the regulation of JAK2 activity 25, 49, 50 . However, structural requirements for JAK2 transphosphorylation -especially in the context of the V617F mutation-have not extensively been studied yet. Although cytokine-induced JAK2 phosphorylation was markedly reduced but still detectable in JAK2 harboring the SH2 mutation, the SH2 domain seems to be indispensable for constitutive JAK2V617F activation. An explanation for this discrepancy might be due to the fact that the SH2 domain mediates transphosphorylation when oncogenic JAKV617F is associated with a cytokine receptor in the absence of ligands.
In the presence of ligands leading to the annealing of the receptor chains, the SH2 domain seems to be important for full activation, but not absolutely required. The notion that close proximity of receptor chains might overcome the strict requirement for the SH2 domain is further supported by the fact that a high density of EpoR on the cell surface is able to rescue the SH2 mutation. This observation might be explained by a higher density of receptor-bound model, we did not detect any difference in kinase activity between SH2-unmutated andmutated JAK2V617F. Instead, we raised two hypotheses, which might explain our findings.
First, JAK2V617F self-aggregation is dependent on the binding between the SH2 domain and a region within the JAK2 molecule, which has not been defined yet. Second, the SH2 domain may be important for intrastructural integrity of the JAK2V617F protein, which is a prerequisite for proper complex formation, transphophorylation and signal transduction. To address these questions, the crystal structure of JAK2V617F would be of great interest.
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